the relationship between the clotting cascade and the promotion or inhibition of the anti - inflammatory response continues to be defined through basic research . the potential key role of proteins that were originally believed to be exclusively involved in coagulation in the inflammatory response provides an exciting potential mechanism(s ) for modification through the application of new therapies . the accompanying review by riewald and ruf   outlines the available information on the possible steps involving some of the various proteins that are common to both coagulation and inflammation . the complexity of the multiple actions of the proteins in both inflammation and coagulation should excite the clinician with regard to potential new therapies that may be beneficial via activation of one or both of the concurrent pathways . however , before clinicians can administer new therapies that utilize new knowledge on the actions of coagulation cascade components , and hence improve the outcomes of their patients , several gaps in our current understanding must be addressed . this information is imperative if the clinician is to take basic knowledge ' to the bedside ' , where individual patients can benefit . administration of intrinsic or synthetic analogues of coagulation cascade components ( e.g. protein c , thrombin , and factor viia or xa ) , coagulation inhibitors ( e.g. heparin or analogues ) , or agonists or antagonists of the protease - activated receptors , in an attempt to alter the individual patient 's coagulation / inflammation balance , could theoretically produce responses ranging from beneficial to detrimental . knowledge of the ' most beneficial ' balance between augmenting or inhibiting the contribution of the clotting cascade components to inflammation would be required for determining the selection and dosing of potential new therapies . a safe assumption is that any new therapies that alter the intrinsic response to coagulation and inflammatory stimulants would also potentially produce detrimental effects on these , and potentially other , physiological responses . a simple example of such a potential for detrimental effects is the administration of protein c resulting in undesirable haemorrhage . this example illustrates that a broader knowledge of the impact of altering the coagulation/ inflammatory response will be required before clinicians can comfortably utilize new therapies in patient care . it is unlikely that any new therapies resulting from the new knowledge of the contribution of the clotting cascade to inflammation can be applied to all patients . it can be anticipated that certain patients would have contraindications to the new therapies or that dosages would need to be adjusted on the basis of pharmacokinetic or pharmacodynamic variables . the clinician will need to know what these contraindications and variables are before the new therapies can be used confidently . some , such as coagulation disorders , may be known and obvious , but any new strategies that could potentially alter the balance of a complex physiological response may be anticipated to be influenced by many , as yet unknown , factors in the individual patient . an example is the concurrent administration of heparin , which appears to antagonize the anti - inflammatory effect of antithrombin iii in septic patients . a more complete understanding of the impact of concurrent conditions , therapies and the patient 's genetic make - up on outcome will be required if we are to obtain the maximum benefit from new therapies . for any new therapy resulting from our expanded knowledge of the clotting cascade in the inflammatory response to be tailored to the needs of the individual patient , a method(s ) for rapidly and easily assessing the patient 's dynamic inflammatory response will be required . unless any new therapies have very benign toxicities , the need to assess the need , dosage and response to treatment will mandate sensitive and specific monitoring techniques . bedside or clinical laboratory techniques that could be applicable to most clinical environments would allow the benefit of any new therapies to be applied to the greatest number of patients . conversely , any new treatments that require complex , laborious monitoring techniques will have limited applicability . as our knowledge of the contribution of the intrinsic coagulation components increases , the development of many potential new therapies will hopefully emerge for clinical use . these may be totally new therapeutic entities or new strategies for using existing drugs or clotting factors . such developments will create the new dilemma for the clinician , namely that of trying to select between different treatment options for the individual patient . clinical trials outlining the potential anticipated benefit(s ) and the appropriate target patient population for each new therapeutic strategy will need to be completed . this will allow the clinician to ensure that the most appropriate strategy can be selected for the individual patient . the above - mentioned concerns aside , the clinician should be excited about the expanding knowledge of the role of coagulation cascade components in modifying the inflammatory response . such knowledge will hopefully result in new strategies and therapies to manage the septic patient .
the relationship between blood coagulation factors and the promotion or inhibition of the anti - inflammatory response continues to be defined through basic research . 
 the potential key role of blood coagulation factors in the response during sepsis provides an exciting potential mechanism(s ) for modification through the application of new therapies . 
 the complexity of the potential multiple actions of the proteins , such as protein c , should allow for development of new therapies to minimize the detrimental inflammatory response . 
 however , several gaps in our current understanding must be bridged before the clinician can take the basic knowledge ' to the bedside ' , where individual patients will benefit .